BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.

Accumen Inc., the leader in healthcare performance, today announced that it will be celebrating the grand opening of its new corporate headquarters in Phoenix, Arizona on Feb. 7.

A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.”

Pharmapack Europe (#PharmapackEU), announces the winners of the 2020 Pharmapack Awards. Due to the outstanding quality of entries, eight worthy winners were chosen across two categories: ‘Exhibitor Innovations’ and ‘Health Products’.

Last week, MassBio® launched a new mentoring program, MassCONNECT.DH, to support the growth and success of digital health startups in Massachusetts.

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings.

Cambridge, UK: Synthetic biology company, Camena Bioscience, announces the achievement of another significant DNA synthesis technology milestone. Using gSynth, a novel multi-enzymatic de novo DNA synthesis and gene assembly technology, Camena Bioscience has produced a whole plasmid of 2.7kb.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Portola Pharmaceuticals, Inc. between November 5, 2019 and January 9, 2020, inclusive, of the important March 16, 2020 lead plaintiff deadline in the securities class action.

Eisai announced the presentation of three abstracts at the 2020 Genitourinary Cancers Symposium in San Francisco from February 13-15.

Seelos Therapeutics, Inc. announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share.